ealthcare osts
Discussion and Debate
Commentary: Reconsidering Pharmaceutical Research and Development Investments
Marc-André Gagnon
Invited Paper
Expensive Drugs for Rare Diseases in Canada: What Value and At What Cost?
Sandra Sirrs, Helen Anderson, Bashir Jiwani, Larry D. Lynd, Eric Lun, Bob Nakagawa, Dean Regier, Shi...
Commentary
Specific, Fair and Transparent: A Canadian Process for Funding Drugs for Rare Diseases
Helen Stevenson
Commentary
What Procedural Ethics Can Learn from the Quest for Moral Justification for the “Rule of Rescue”
Bernard Keating
Commentary
Expensive Drug Prices for Rare Cancers: Are Patients Truly Benefitting?
Kristina Jenei and Bishal Gyawali
Commentary
Can Managed Access Agreements Mitigate Evidentiary, Economic and Ethical Issues with Access to Expensive Drugs for Rare Diseases in the Canadian Context?
Melanie McPhail and Tania Bubela